Oxford Asset Management’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-100,151
| Closed | -$886K | – | 2095 |
|
|
2018
Q2 | $886K | Buy |
100,151
+35,434
| +55% | +$319K | 0.02% | 1105 |
|
|
2018
Q1 | $657K | Buy |
+64,717
| New | +$544K | 0.01% | 1129 |
|
|
2016
Q3 | – | Sell |
-19,646
| Closed | -$138K | – | 928 |
|
|
2016
Q2 | $138K | Sell |
19,646
-21,595
| -52% | -$152K | ﹤0.01% | 720 |
|
|
2016
Q1 | $273K | Sell |
41,241
-7,956
| -16% | -$58.5K | 0.01% | 686 |
|
|
2015
Q4 | $496K | Buy |
+49,197
| New | +$570K | 0.01% | 673 |
|
|
2015
Q3 | – | Sell |
-33,107
| Closed | -$303K | – | 767 |
|
|
2015
Q2 | $303K | Buy |
33,107
+15,243
| +85% | +$115K | 0.01% | 565 |
|
|
2015
Q1 | $111K | Sell |
17,864
-17,443
| -49% | -$108K | ﹤0.01% | 631 |
|
|
2014
Q4 | $194K | Sell |
35,307
-4,200
| -11% | -$24.5K | ﹤0.01% | 629 |
|
|
2014
Q3 | $234K | Sell |
39,507
-12,818
| -24% | -$78.2K | 0.01% | 618 |
|
|
2014
Q2 | $360K | Sell |
52,325
-16,729
| -24% | -$112K | 0.01% | 604 |
|
|
2014
Q1 | $499K | Sell |
69,054
-1,854
| -3% | -$12.8K | 0.01% | 519 |
|
|
2013
Q4 | $469K | Buy |
70,908
+21,360
| +43% | +$145K | 0.01% | 594 |
|
|
2013
Q3 | $360K | Buy |
+49,548
| New | +$334K | 0.01% | 688 |
|
Oxford Asset Management's JNP Position: Q3 2018 in Review
Oxford Asset Management sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 100,151 shares — an estimated $886K sold.
Oxford Asset Management first reported a position in JNP in Q3 2013 and held it in 13 quarters. The position peaked at $886K in Q2 2018. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.
- Oxford Asset Management reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
- Oxford Asset Management sold 100,151 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $886K.
- Oxford Asset Management first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q3 2013 and held it in 13 quarters.
- Oxford Asset Management's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $886K in Q2 2018.
- 0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.
Based on Oxford Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.